RxDoctor Payments Data

Nicole Xanders-Danler

Psychiatric/Mental Health · Wichita, KSNPI 1083374292

Payments from drug & device makers

$2,783in general payments, 2019–2025

Across 168 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$451
  • Johnson & Johnson$443
  • Alkermes, Inc.$308
  • Otsuka America Pharmaceutical, Inc.$297
  • Vanda Pharmaceuticals Inc.$215
  • Indivior Inc.$205
  • plus $865 from 12 others

What the payments were for

  • Food & beverage$2,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,783 in reported general payments places this provider in the 80th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$7,667
Medicare patients
27
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate32$87,696
VraylarCariprazine Hcl21$28,618
Aripiprazole54$1,127
Olanzapine52$735
Bupropion XlBupropion Hcl47$585
Risperidone45$490
Divalproex Sodium ErDivalproex Sodium23$418
Haloperidol13$360
Quetiapine Fumarate21$337
Haloperidol Decanoate17$303
Benztropine Mesylate32$292
Mirtazapine36$243
Duloxetine Hcl12$222
Paroxetine Hcl13$190
Trazodone Hcl30$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$443$87,69632 claims
AbbVieVraylar$107$28,61821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →